In conclusion, 6-benzoyl-benzothiazol-2-one is a scaffold that could be substituted to develop therapeutic agents for diabetes and/or serve as a lead compound for further drug design studies targeting PPAR-γ and PPARα for effective management of type 2 diabetes and dyslipidemia without inducing weight gain. Here, PPARA is linked to metabolic syndrome.